Navigation Links
Zevalin in Medical News

Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US

SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) (Nasdaq and MTA: CTIC) announced today they have closed the transaction with Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumoma...

Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma

SEATTLE, Dec. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that the results of three Italian multicenter studies utilizing Zevalin(R) ([90Y]-ibritumomab tiuxetan) were presented at the American Society of Hematology (ASH) 50th Annual Meeting in San Fra...

FDA Approves Anti-Cancer Cell Drug - Zevalin

The government approved a long-awaited treatment for lymphoma - a drug that uses a novel approach to bring radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes the first radioimmunotherapy drug cleared to sell in the US. // It's a new approach, adding radiation to antibod...

Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009

...s, Inc. associated with the initial divestiture of zevalin to the joint venture with Spectrum and the subsequ... one-time gain on the sale CTI's investment in the zevalin joint venture coupled with a decrease in research ...penses and gain on sale of CTI's investment in the zevalin joint venture. CTI had approximately $0.7 mil...

Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma

...onstrating that rituximab followed by single agent zevalin (ibritumomab tiuxetan) in a front-line setting for...erefore, systemic targeted radioimmunotherapy with zevalin might offer an alternative to treating OAL. "This study demonstrates the potential for zevalin to provide an alternative to EBRT, the current sta...

Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals

...al Biologics License Application (sBLA) for use of zevalin as consolidation therapy in patients with follicul...A in early April, 2009. About Zevalin(R) zevalin (R) (Ibritumomab Tiuxetan) is a form of cancer th...radioimmunotherapy and is indicated as part of the zevalin therapeutic regimen for treatment of relapsed or r...

Zevalin Data to be Presented at ASH 2008

...ectrum announced on November 26, 2008 that they have entered into an agreement to form a joint venture, RIT Oncology LLC, to commercialize and develop zevalin in the United States. Presentation/ Date/Time Abstract # Poster # Title Saturday, Dec. ...

Craig W. Philips Takes Helm at CTI

...aluated the benefit and safety of a single dose of zevalin in patients with CD20-positive follicular lymphoma...radioimmunotherapy and is indicated as part of the zevalin therapeutic regimen for treatment of relapsed or r...patients with rituximab refractory follicular NHL. zevalin is also indicated, under accelerated approval, for...

Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results

...ed expenses related to the creation of commercial infrastructure to support zevalin and fees associated with capital structure advisory services. Net loss attr...ategy to focus resources on our late-stage development products and growing zevalin sales. With our commercial team now in place to support Zevalin, we expect ...

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results

...nt payment of $10.1 million and initiated building zevalin sales, marketing, and medical affairs infrastructu... focusing resources on reaching $15 million in net zevalin revenues, pursuing European marketing authorizatio...ignment completed, we can focus on commercializing zevalin and developing our late- stage product pipeline." ...
Zevalin in Medical Technology

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

...ement in progression-free survival (PFS) following zevalin consolidation therapy for patients with follicular...ine therapy over chemotherapy alone. Additionally, zevalin consolidation did not adversely affect the use of ... that the median progression free survival for the zevalin recipients that achieved a complete remission (CR)...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

...igating the use of short-course CHOP-R followed by zevalin ([90Y]-ibritumomab tiuxetan) and extended rituxima...r non-Hodgkin's lymphoma patients. Addition of the zevalin therapeutic regimen increased the complete respons...ed after 3 cycles of CHOP-R alone to 82% after the zevalin regimen. "This study adds to recently published ...

Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma

...U.S. Food and Drug Administration (FDA) for use of zevalin in first-line consolidation therapy based on the F...tologist/oncologists the ability to offer RIT with zevalin to their patients eliminating many of the current ...ted the benefit and safety of a single infusion of zevalin in 414 patients with CD20-positive follicular non-...

CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)

... September meeting to focus on use of zevalin as consolidation therapy after remission inductio...ting with the FDA to discuss a label expansion for zevalin which could broaden its availability to patients,"...l Therapeutics. "We continue to make progress with zevalin on multiple fronts with clarity on reimbursement r...

Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

...peutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets zevalin in the United States. "In a high risk, elderly p...le for a registration-directed randomized trial of zevalin consolidation in higher risk patients with DLBCL."...veloped myelodysplasia and two patients died after zevalin was given, one from a suspected brain hemorrhage a...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

...ory. Patients were treated with a standard dose of zevalin administered with 2.5 to 5.0 mg/kg of MGd given fo...acyclics, and a co-author on the lymphoma study. zevalin is a radiolabeled antibody approved for treatment of patients with relapsed non-Hodgkin's lymphoma. zevalin binds to tumor cells and emits radiation to the tu...

Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

...radioimmunotherapy and is indicated as part of the zevalin therapeutic regimen for treatment of relapsed or r...eported. The most serious adverse reactions of the zevalin therapeutic regimen were primarily hematologic, in...ith the degree of bone marrow involvement prior to zevalin therapy. Myelodysplasia or acute myelogenous leuke...

Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma

... was to determine the tolerability and efficacy of zevalin consolidation following sequential fludarabine and...y treated with Zevalin therapy. Consolidation with zevalin converted 12 of 14 partial remissions (86 percent)...x cycles of therapy indicating that treatment with zevalin did not preclude the ability to administer an aggr...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

...eported. The most serious adverse reactions of the zevalin therapeutic regimen were primarily hematologic, in...ith the degree of bone marrow involvement prior to zevalin therapy. Myelodysplasia or acute myelogenous leuke...cent of patients (8 to 34 months after treatment). zevalin should only be used by health care professionals q...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

...Comprehensive Cancer Center, used a single dose of zevalin in patients undergoing ASCT following HDC with the...llowing the Zevalin-based regimen. The addition of zevalin to the BEAM regimen did not appear to add to the t...afety and efficacy of combining a standard dose of zevalin (14.8 MBq/kg [0.4mCi/kg]) followed by high-dose BE...
Zevalin in Biological Technology

CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture

SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it received $6.5 million from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the sale of its 50% interest in the Zevalin joint venture to Spectrum for approximately $1...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmac...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is seeking to obtain two new drug approvals...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for ...

Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the agreement with Spectrum Pharmaceuticals of Irv...

Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals

SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the agreement with Spectrum Pharmaceut...

Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy

Approval would make Zevalin only Radioimmunotherapy in U.S. to be Indicated for Use in First-Line Therapy SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental Biologics License Appl...

Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference

...losure of its Bresso, Italy pre-clinical research operation and employees associated with Zevalin. CTI recently sold its remaining 50% interest in the zevalin joint venture to Spectrum Pharmaceuticals for approximately $16.5 million. About Cell Therapeutics, Inc. Headquartered in Seattl...

Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results

...ion. Potential approval by end of 2009. zevalin sales prior to the establishment of the joint vent...n in 2008. Sold an initial 50% interest in zevalin to a 50/50 owned joint venture with Spectrum for $...er 2008 and sold the remaining 50% interest in the zevalin joint venture to Spectrum for approximately $16.5 ...

Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug

...000 patients per year would be eligible to receive zevalin in this setting. We assembled an experienced sale...ss, to launch our recently approved drug FUSILEV. zevalin represents a complementary product that our sales ...s in the near-term and reduce our costs to develop zevalin for new growth opportunities, resulting in an incr...
Other Tags
(Date:10/25/2014)... (PRWEB) October 25, 2014 More than ... President’s Circle Reception on Monday at the home of ... and hear from guest speaker Dr. Winifred Lender on ... , Dr. Lender, a Santa Barbara psychologist, author and ... and benefits of living in the digital age. Our ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... Minnesota (PRWEB) October 25, 2014 ... testing firm which verifies IT-accessibility for disabled users ... Access Approved® logo to Mackin Educational Resources ... digital resource management system and to the Minnesota ... the "Own Best Medicine" website. ...
(Date:10/25/2014)... Dallas, TX (PRWEB) October 25, 2014 ... and Chinese Molecular Diagnostics Industry, 2009-2019 is ... Global and Chinese Molecular Diagnostics industry. The ... Molecular Diagnostics including its classification, application and ... and China’s top manufacturers of Molecular Diagnostics ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4
(Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions , ... study management systems, is pleased to announce the 2014 ... event – to be held in Bloomington, ... track to have record attendance and promises to be ... The focus of the meeting is ...
(Date:10/25/2014)... LONDON , Oct. 22, 2014 This ... is a relatively new space in heavy pursuit of ... are unique to miRNAs compared to other RNA components. ... make it a novel candidate for use as a ... pursuit of miRNA-based microarrays and diagnostics for the advancement ...
(Date:10/25/2014)... , Oct. 22, 2014 A recent report, ... of the current and future genetic testing market. A ... types are covered in this report. On account of ... drivers; and existing strengths and challenges; forecast for genetic ... is likely to grow at a CAGR of around ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
Other Contents